News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
10,690 Results
Type
Article (214)
Company Profile (13)
Press Release (10463)
Section
Business (2766)
Career Advice (5)
Deals (349)
Drug Development (1210)
Employer Resources (3)
FDA (210)
Job Trends (377)
News (4315)
Policy (269)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 Genetown Standard (2)
Academia (36)
Accelerated approval (1)
Allergies (3)
Alliances (591)
ALS (16)
Alzheimer's disease (40)
Antibody-drug conjugate (ADC) (22)
Approvals (229)
Artificial intelligence (13)
ASCO (21)
Autoimmune disease (10)
Automation (1)
Bankruptcy (3)
Belgium (2)
Best Places to Work (364)
BIO (1)
Biologics (6)
Biosimilars (1)
Biotechnology (12)
Bispecific (2)
Bladder cancer (5)
Brain cancer (10)
Breast cancer (62)
Cancer (254)
Cardiovascular disease (3)
Career advice (4)
CAR-T (14)
CDMO (3)
Cell therapy (39)
Clinical research (1210)
Collaboration (57)
Commercialization (1)
Compensation (69)
Complete response letters (3)
COVID-19 (17)
CRISPR (2)
C-suite (51)
Cystic fibrosis (1)
Data (372)
Depression (4)
Dermatology (3)
Diabetes (7)
Diagnostics (104)
Digital health (1)
Diversity, equity & inclusion (2)
Drug discovery (8)
Duchenne muscular dystrophy (20)
Earnings (1026)
Employer resources (3)
ESMO (21)
Events (2624)
Executive appointments (39)
FDA (328)
Friedreich's ataxia (1)
Frontotemporal dementia (7)
Funding (45)
Gene editing (3)
Generative AI (1)
Gene therapy (20)
GLP-1 (14)
Government (41)
Guidances (7)
Healthcare (340)
Hematology (9)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (2)
Immunology and inflammation (6)
Immuno-oncology (1)
Indications (5)
Infectious disease (22)
Inflammatory bowel disease (7)
Influenza (1)
Intellectual property (13)
Interviews (1)
IPO (156)
Job creations (23)
Job search strategy (4)
Kidney cancer (2)
Kidney disease (5)
Layoffs (3)
Legal (52)
Licensing (1)
Liver cancer (3)
Lung cancer (25)
Lymphoma (9)
Machine learning (1)
Manufacturing (25)
Marketing (1)
MASH (2)
Medical device (249)
Medtech (271)
Mergers & acquisitions (226)
Metabolic disorders (15)
mRNA (3)
Multiple sclerosis (8)
Netherlands (2)
Neurodegenerative disease (11)
Neuropsychiatric disorders (1)
Neuroscience (92)
NextGen: Class of 2026 (146)
Non-profit (102)
Obesity (4)
Opinion (2)
Ovarian cancer (4)
Pain (18)
Pancreatic cancer (25)
Parkinson's disease (7)
Patents (24)
Patient recruitment (35)
Patient selection (4)
People (1017)
Phase 1 (510)
Phase 2 (539)
Phase 3 (308)
Pipeline (382)
Postmarket research (33)
Preclinical (242)
Prostate cancer (13)
Psychedelics (1)
Radiopharmaceuticals (31)
Rare diseases (42)
Real estate (98)
Recruiting (1)
Regenerative medicine (1)
Regulatory (322)
Research institute (34)
Resumes & cover letters (1)
Rett syndrome (1)
RNA editing (1)
Series A (11)
Series B (5)
Service/supplier (1)
Sickle cell disease (13)
Sponsored (1)
Startups (38)
Substance use disorders (1)
Tariffs (1)
Vaccines (10)
Weight loss (1)
Wet AMD (1)
Women's health (6)
Date
Today (4)
Last 7 days (28)
Last 30 days (88)
Last 365 days (791)
2026 (697)
2025 (810)
2024 (955)
2023 (936)
2022 (925)
2021 (955)
2020 (732)
2019 (687)
2018 (518)
2017 (376)
2016 (394)
2015 (437)
2014 (326)
2013 (227)
2012 (275)
2011 (288)
2010 (260)
Location
Africa (10)
Alabama (1)
Arizona (1)
Arkansas (1)
Asia (246)
Australia (201)
California (282)
Canada (36)
China (25)
Colorado (4)
Connecticut (24)
Delaware (5)
Europe (1063)
Florida (98)
Georgia (3)
Idaho (1)
Illinois (56)
Indiana (41)
Iowa (1)
Japan (10)
Kentucky (2)
Maryland (21)
Massachusetts (459)
Michigan (1)
Minnesota (3)
Missouri (1)
New Hampshire (2)
New Jersey (51)
New York (57)
North Carolina (71)
North Dakota (1)
Northern California (96)
Ohio (5)
Oregon (1)
Pennsylvania (63)
Puerto Rico (1)
Rhode Island (2)
South America (10)
Southern California (165)
Tennessee (3)
Texas (574)
United States (1796)
Utah (5)
Virginia (2)
Washington D.C. (2)
Washington State (14)
Wisconsin (1)
10,690 Results for "Obsidian_Tx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting
November 6, 2026
·
9 min read
Press Releases
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
October 4, 2026
·
5 min read
Press Releases
Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
August 3, 2026
·
8 min read
Press Releases
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
August 5, 2026
·
6 min read
Press Releases
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
July 22, 2026
·
8 min read
Press Releases
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
April 15, 2026
·
13 min read
Press Releases
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
April 15, 2026
·
13 min read
Press Releases
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
September 24, 2026
·
7 min read
Press Releases
Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer
January 13, 2026
·
2 min read
Press Releases
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
May 22, 2026
·
11 min read
1 of 1,069
Next
